SecSonar.com

IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

IDEAYA Biosciences, Inc. (IDYA) is a Biotechnology company based in US with a market capitalization of $2.6B. Revenue grew 3024.4% year-over-year and free cash flow was negative at -$73.5M. This page tracks IDYA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 131 employees · IPO May 23, 2019

Valuation

Valuation & price

$28.21 · as of May 17, 2026 · -25.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.54

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$37.65$29.41$21.16Jul 25Dec 25Jul 26Jul 7, 25$21.16Jul 9, 25$22.97Jul 11, 25$22.48Jul 15, 25$21.43Jul 17, 25$22.09Jul 21, 25$21.81Jul 23, 25$23.63Jul 25, 25$24.50Jul 29, 25$24.84Jul 31, 25$24.35Aug 4, 25$25.00Aug 6, 25$23.63Aug 11, 25$22.84Aug 13, 25$24.42Aug 15, 25$24.33Aug 19, 25$24.05Aug 21, 25$24.63Aug 25, 25$24.71Aug 27, 25$25.00Aug 29, 25$24.55Sep 3, 25$25.76Sep 5, 25$27.16Sep 9, 25$24.74Sep 11, 25$24.93Sep 16, 25$24.72Sep 18, 25$26.22Sep 22, 25$25.92Sep 24, 25$25.67Sep 26, 25$26.83Sep 30, 25$27.21Oct 2, 25$27.20Oct 6, 25$27.49Oct 8, 25$26.84Oct 10, 25$26.24Oct 14, 25$27.07Oct 16, 25$27.69Oct 21, 25$29.20Oct 23, 25$28.42Oct 27, 25$32.37Oct 29, 25$32.18Oct 31, 25$31.86Nov 4, 25$30.48Nov 6, 25$29.85Nov 10, 25$30.89Nov 12, 25$31.95Nov 14, 25$32.14Nov 18, 25$33.71Nov 20, 25$33.16Nov 25, 25$35.49Nov 28, 25$35.62Dec 2, 25$33.69Dec 4, 25$36.01Dec 8, 25$35.34Dec 10, 25$33.64Dec 12, 25$34.02Dec 16, 25$33.81Dec 18, 25$33.26Dec 22, 25$35.50Dec 24, 25$35.68Dec 29, 25$34.84Jan 2, 26$33.85Jan 6, 26$36.31Jan 8, 26$36.43Jan 12, 26$36.84Jan 14, 26$37.03Jan 16, 26$35.84Jan 21, 26$36.01Jan 23, 26$34.80Jan 27, 26$34.74Jan 29, 26$32.99Feb 2, 26$34.06Feb 4, 26$33.28Feb 9, 26$32.39Feb 11, 26$31.90Feb 13, 26$30.27Feb 18, 26$30.92Feb 20, 26$31.98Feb 24, 26$32.07Feb 26, 26$31.90Mar 2, 26$33.04Mar 4, 26$34.68Mar 6, 26$33.19Mar 10, 26$34.74Mar 12, 26$32.83Mar 17, 26$34.27Mar 19, 26$32.60Mar 23, 26$31.64Mar 25, 26$31.39Mar 27, 26$30.46Mar 31, 26$33.32Apr 2, 26$32.74Apr 7, 26$30.91Apr 9, 26$31.00Apr 13, 26$32.82Apr 15, 26$32.18Apr 17, 26$33.91Apr 22, 26$31.67Apr 24, 26$30.73Apr 28, 26$29.04Apr 30, 26$29.10May 4, 26$28.90May 6, 26$28.74May 8, 26$28.32May 12, 26$28.12May 14, 26$28.84May 18, 26$28.32May 20, 26$29.65May 22, 26$29.10May 28, 26$29.34Jun 1, 26$28.94Jun 3, 26$28.40Jun 5, 26$28.29Jun 9, 26$28.07Jun 11, 26$28.84Jun 15, 26$30.23Jun 17, 26$31.26Jun 22, 26$34.23Jun 24, 26$36.28Jun 26, 26$36.74Jul 2, 26$37.65
$21.1652-week range$37.86
Loading valuation history…

Fundamentals

Key fundamentals

$2.6B

Market cap

3024.4%

Revenue growth (YoY)

97.9%

Gross margin

-$73.5M

Free cash flow (USD)

-$611.5M

Net debt

Net cash position

8.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$19.5MFY 2021$27.9MFY 2022$50.9MFY 2023$23.4MFY 2024$7.0MFY 2025$218.7M
$0$218.7M

Free cash flow by year

2017 → 2025

FY 2017$-14.0MFY 2018$-29.3MFY 2019$-40.7MFY 2020$55.0MFY 2021$-58.4MFY 2022$-90.6MFY 2023$-117.6MFY 2024$-251.4MFY 2025$-73.5M
-$14M-$73.5M

Gross margin by year

2021 → 2025

FY 202193.8%FY 202295.9%FY 202382.9%FY 202445.2%FY 202597.9%
93.8%97.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 23, 2026Filing
  • 8-K eventStock OfferingJun 10, 2026Filing
  • 8-K eventClinical Collaboration AnnouncedJun 3, 2026Filing
  • 8-K eventClinical Trial Data PresentationJun 1, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • FinancingSecurities RegistrationMay 5, 2026Filing
  • 8-K eventShelf Registration StatementMay 5, 2026Filing
  • 8-K eventClinical Trial ResultsApr 13, 2026Filing
  • 8-K eventClinical Collaboration AgreementApr 9, 2026Filing

Questions

Frequently asked questions

What is IDEAYA Biosciences, Inc.'s market cap?

IDEAYA Biosciences, Inc. (IDYA) has a market capitalization of $2.6B.

What is IDYA's P/E ratio?

A meaningful P/E ratio is not available for IDYA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is IDYA's price-to-book (P/B) ratio?

IDYA trades at 2.54 times book value per share.

Are insiders buying IDYA stock?

SEC Form 4 filings show no open-market insider buys at IDEAYA Biosciences, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

TARS

Tarsus Pharmaceuticals, Inc.

$2.6B

ALMS

Alumis Inc. Common Stock

$2.7B

RCUS

Arcus Biosciences, Inc.

$2.5B

ARQT

Arcutis Biotherapeutics, Inc.

$2.7B

ADPT

Adaptive Biotechnologies Corporation

$2.5B

TNGX

Tango Therapeutics, Inc.

$2.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.